Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DermTech, Inc. stock logo
DMTK
DermTech
$0.19
$0.09
$3.90
$3.29M2.481.07 million shs3.66 million shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.34
$0.25
$1.28
$17.03M1.19167,188 shs4.12 million shs
Genetron Holdings Limited stock logo
GTH
Genetron
$4.03
$3.98
$2.08
$4.05
$127.27M0.5151,662 shs412,603 shs
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
$11.34
$10.79
$8.43
$12.83
$83.80M-0.049,656 shs183,276 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DermTech, Inc. stock logo
DMTK
DermTech
0.00%0.00%0.00%0.00%-81.14%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%-33.67%-72.46%
Genetron Holdings Limited stock logo
GTH
Genetron
0.00%0.00%0.00%-0.12%-0.12%
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/AN/AN/AN/AN/AN/A
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DermTech, Inc. stock logo
DMTK
DermTech
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
0.00
N/AN/AN/A
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DermTech, Inc. stock logo
DMTK
DermTech
$15.66M0.00N/AN/A$1.67 per share0.00
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Genetron Holdings Limited stock logo
GTH
Genetron
$94.34M1.35N/AN/A$2.63 per share1.53
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
N/AN/A$0.89 per share12.80($2.04) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DermTech, Inc. stock logo
DMTK
DermTech
-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%6/12/2025 (Estimated)
Genetron Holdings Limited stock logo
GTH
Genetron
-$117.21MN/A0.00N/AN/AN/AN/AN/A
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
$5.54MN/A0.00N/AN/A-17.92%-1.48%N/A

Latest MTAC, GTH, DMTK, and ENZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/17/2025Q2 2025
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A-$0.02N/A-$0.03N/A$7.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/AN/AN/A
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DermTech, Inc. stock logo
DMTK
DermTech
N/A
3.53
3.46
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/A
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
N/A
0.03
0.03

Institutional Ownership

CompanyInstitutional Ownership
DermTech, Inc. stock logo
DMTK
DermTech
20.45%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Genetron Holdings Limited stock logo
GTH
Genetron
10.74%
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
20.96%

Insider Ownership

CompanyInsider Ownership
DermTech, Inc. stock logo
DMTK
DermTech
5.10%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Genetron Holdings Limited stock logo
GTH
Genetron
N/A
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
76.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
DermTech, Inc. stock logo
DMTK
DermTech
26034.96 million33.18 millionOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Genetron Holdings Limited stock logo
GTH
Genetron
99331.62 millionN/ANot Optionable
MedTech Acquisition Co. stock logo
MTAC
MedTech Acquisition
37.39 million1.95 millionNot Optionable

Recent News About These Companies

Medtech M&A sees fewer deals but more money in Q1
Medtech M&A sees fewer deals but more money in Q1
5 medtech notes: Medtronic, Stryker and more
Top 10 medtech deals of 2024
9 spine, orthopedic medtech mergers in 2024
Medtech: Capitalize On These 4 Trends To Thrive In 2025
Boston Scientific closes Silk Road Medical acquisition
How to build your career amid medtech M&A, spinoffs and layoffs
Top 5 medtech deals in the first half of 2024
SMTI Sanara MedTech Inc.

Media Sentiment Over Time

Top Headlines

View All Headlines
DermTech stock logo

DermTech NASDAQ:DMTK

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Genetron stock logo

Genetron NASDAQ:GTH

Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.

MedTech Acquisition stock logo

MedTech Acquisition NASDAQ:MTAC

MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare sector in the United States. The company was incorporated in 2020 and is based in Greenwich, Connecticut. MedTech Acquisition Corporation operates as a subsidiary of Medtech Acquisition Sponsor LLC.